On the other hand, the development of specific agonists to target adiponectin and omentin receptors or inhibit detrimental adipokine signalling pathways may be new and promising methods to attenuate the proinflammatory effects and ultimately to reduce the progression of obesity-related vascular diseases. This evidence concerns the gene ADIPOQ and Obesity.